Enzyvant

Apr 03, 2019

Enzyvant's Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting

Mar 21, 2019

Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

Feb 21, 2019

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

Feb 04, 2019

Enzyvant to Highlight Investigational RVT-801 Program and Farber Disease Natural History Study at Upcoming WORLDSymposium(TM)

Jul 30, 2018

Enzyvant Expands Leadership Team with Appointments of Andrew Dawson and Alex Tracy

Jul 19, 2018

Enzyvant Announces Collaboration with PerkinElmer to Enable Diagnostic Testing for Farber Disease

Jul 09, 2018

Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly

Jul 05, 2018

Enzyvant Announces Collaboration with Visikol to Develop Innovative Digital Pathology Assay to Support RVT-802 Development

Jun 04, 2018

Enzyvant Expands Executive Leadership Team with Appointments of Alan Kimura as Chief Medical Officer and Tamara Joseph as General Counsel

Feb 28, 2018

Enzyvant Launches Re:GenerationHope Initiative in Honor of Rare Disease Day 2018

Oct 16, 2017

Enzyvant Initiates Farber Disease Natural History Study

Sep 05, 2017

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802